NCT06339619View on ClinicalTrials.gov

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

September 1, 2026

Conditions
Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Adebrelimab

20mg/kg ivgtt D1 Q3W

DRUG

Apatinib

250mg PO QD

DRUG

Tegafur

dosing based on body surface area：BSA\<1.25m2,40mg; BSA=1.25～1.5m2,50mg; BSA\>1.5m2, 60mg，PO QD D1-21 Q3W

Trial Locations (1)

510030

RECRUITING

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER